Its prevalence rate in the general population is as high as more than 25% ( Chan et al., 2023 ), and it is showing an increasing trend year by year, seriously threatening human public health.
← all excerpts
Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease.
1
—
—